Hypocholesterolemia in patients treated with recombinant interleukin-2: appearance of remnant-like lipoproteins.
Reversible acute hypocholesterolemia was observed during treatment of metastatic cancer with high-dose intravenous recombinant interleukin-2 (IL-2). Further analysis revealed virtual disappearance of high-density lipoproteins (HDLs) and marked reduction in the concentration of low-density lipoproteins (LDL); the remaining LDL and intermediate-density lipoproteins (IDL) were enriched in triglyceride relative to cholesterol and had broad-beta electrophoretic mobility, properties reminiscent of remnant lipoproteins. These changes differ qualitatively and quantitatively from those previously reported for other cytokines such as tumor necrosis factor (TNF) or the interferons (IFNs).
Wilson
D E
DE
Veterans Administration Medical Center, Salt Lake City, UT 84148.
Birchfield
G R
GR
Hejazi
J S
JS
Ward
J H
JH
Samlowski
W E
WE
D002784:Cholesterol / Q000097:blood*; D006801:Humans; D007376:Interleukin-2 / Q000009:adverse effects*; D007680:Kidney Neoplasms / Q000628:therapy; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008545:Melanoma / Q000628:therapy; D008659:Metabolic Diseases / Q000097:blood / Q000139:chemically induced*; D011994:Recombinant Proteins; D014280:Triglycerides / Q000097:blood
D007376:Interleukin-2; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D011994:Recombinant Proteins; D014280:Triglycerides; D002784:Cholesterol